Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 83.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (27.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -1.3% (LTM)
  • Share price is 226.9% higher than minimum and 9.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (52.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $2 384.8 mln (-0.097% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-4.7%)869.58
year average price 835.50  


year start price 762.14 2024-03-10

min close price 724.87 2024-04-25

max close price 960.02 2024-08-30

current price 869.58 2025-03-09
Common stocks: 903 782 000

Dividend Yield:  0.6%
FCF Yield LTM: -1.3%
EV / LTM EBITDA: 52.5x
EV / EBITDA annualized: 96.1x
Last revenue growth (y/y):  +20.4%
Last growth of EBITDA (y/y):  +145.9%
Historical revenue growth:  +14.7%
Historical growth of EBITDA:  +39.3%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 785 911
Net Debt ($m): 27 682
EV (Enterprise Value): 813 593
EBITDA LTM ($m): 15 491
EV / LTM EBITDA: 52.5x
Price to Book: 55.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-03-08prnewswire.com

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

2025-03-04seekingalpha.com

Eli Lilly and Company (LLY) TD Cowen 45th Annual Health Care Conference (Transcript)

2025-03-03businesswire.com

Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA

2025-03-03zacks.com

Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe

2025-03-02fool.com

Where Will Eli Lilly Be in 5 Years?

2025-02-28prnewswire.com

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

2025-02-27foxbusiness.com

Eli Lilly investing $27B more in US manufacturing

2025-02-26proactiveinvestors.com

Eli Lilly announces $27B investment in US drug manufacturing

2025-02-26youtube.com

Eli Lilly CEO on $27 billion investment in U.S. manufacturing expansion

2025-02-25investopedia.com

Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data